August 22, 2013
GLAXOSMITHKLINE, LLC, Plaintiff,
GENENTECH, INC., Defendant.
ORDER CONSTRUING THE TERMS OF U.S. PATENT, RE41, 555
Order After having considered the submissions of the parties and hearing oral argument on the matter, IT IS HEREBY ORDERED, ADJUDGED, and DECREED that, as used in the asserted claims of US. Patent No. RE41.555 ("the '555 Patent"):
1. The term "selectively eluting [the monomeric IgG antibody] from the support" and "the antibody selectively eluted" is construed to mean "eluting such that the concentration of contaminants in the mixture relative to the concentration of monomeric IgG antibody is lower compared to what is applied to the column."
2. The term " monomeric IgG antibody" is construed to mean "a monomeric IgG antibody or a monomeric IgG antibody-like protein which may be purified by the protocol described therein."